CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ...
Phase 2
Houston, Texas, United States and 2 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Houston, Texas, United States and 89 other locations
patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...
Phase 1
Houston, Texas, United States and 13 other locations
multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...
Phase 2
Houston, Texas, United States and 16 other locations
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...
Phase 1
Houston, Texas, United States and 31 other locations
Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...
Phase 3
Houston, Texas, United States and 66 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
Houston, Texas, United States and 31 other locations
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....
Phase 1
Houston, Texas, United States and 5 other locations
1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...
Phase 1, Phase 2
Houston, Texas, United States and 3 other locations
in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question t...
Phase 1
Houston, Texas, United States and 2 other locations
Clinical trials
Research sites
Resources
Legal